ITGR — Integer Holdings Corporation stock price, charts and financials
QT75Integer Holdings CorporationInteger Holdings Corporation (NYSE: ITGR) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 29.85 | EPS (ttm) | 4.06 | Insider Own | 2.60% | Shs Outstand | 33.95M | Perf Week | 22.91% |
| Market Cap | 4.12B | Forward P/E | 17.78 | EPS next Y | 6.82 | Insider Trans | -0.09% | Shs Float | 33.46M | Perf Month | 28.17% |
| Enterprise Value | 5.49B | PEG | 0.39 | EPS next Q | - | Inst Own | - | Short Float | 13.01% | Perf Quarter | 36.94% |
| Income | 140.34M | P/S | 2.22 | EPS this Y | 51.73% | Inst Trans | - | Short Ratio | 8.10 | Perf Half Y | 40.18% |
| Sales | 1.85B | P/B | 2.45 | EPS next Y | 12.08% | ROA | 4.16% | Short Interest | 4.35M | Perf YTD | 54.55% |
| Book/sh | - | P/C | 21.92 | EPS next 5Y | 10.77% | ROE | 8.23% | 52W High | 126.80 -1.85% | Perf Year | 11.45% |
| Cash/sh | - | P/FCF | 41.24 | EPS past 3/5Y | 13.82% 4.40% | ROIC | 5.35% | 52W Low | 63.66 95.50% | Perf 3Y | 39.34% |
| Dividend Est. | - | EV/EBITDA | 16.50 | Sales past 3/5Y | 11.52% 11.46% | Gross Margin | 23.31% | Volatility | 6.86% 3.80% | Perf 5Y | 31.85% |
| Dividend TTM | - | EV/Sales | 2.97 | EPS Y/Y TTM | 17.94% | Oper. Margin | 10.41% | ATR (14) | 4.20 | Perf 10Y | 278.78% |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | Sales Y/Y TTM | 7.80% | Profit Margin | 7.67% | RSI (14) | 83.47 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.75 | EPS Q/Q | -8.40% | SMA20 | 24.37% | Beta | 0.61 | Target Price | 107.50 |
| Payout | 0.00% | Debt/Eq | 0.81 | Sales Q/Q | 0.92% | SMA50 | 29.22% | Rel Volume | 4.91 | Prev Close | 121.21 |
| Employees | 11,000 | LT Debt/Eq | 0.79 | Earnings | Aug 06 | SMA200 | 42.57% | Avg Volume | 531.53K | Price | 124.45 |
| IPO Date | Sep 29, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.25% 3.07% | Net Debt/EBITDA | 4.13 | Volume | 2,608,095 | Change | 2.67% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-21-26 | Reiterated | KeyBanc | Overweight | $133 → $104 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $95 → $110 |
| May-13-26 | Upgrade | Oppenheimer | Perform → Outperform | $115 |
| Feb-23-26 | Reiterated | Raymond James | Outperform | $95 → $101 |
| Feb-20-26 | Upgrade | Benchmark | Hold → Buy | |
| Dec-18-25 | Reiterated | Truist Securities | Buy | $86 → $95 |
| Nov-24-25 | Reiterated | Truist Securities | Buy | $88 → $86 |
| Oct-24-25 | Downgrade | Citigroup | Buy → Neutral | |
| Oct-24-25 | Reiterated | Piper Sandler | Overweight | $82 |
| Oct-24-25 | Reiterated | Raymond James | Outperform | $95 |
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,851 | 1,846 | 1,717 | 1,556 | 1,331 | 1,221 | 1,073 | 1,258 | 1,215 | |
| Cost of Goods Sold Incl. D&A | 1,419 | 1,421 | 1,255 | 1,144 | 985 | 884 | 788 | 903 | 852 | |
| Gross Profit | 431 | 426 | 461 | 412 | 347 | 337 | 286 | 355 | 363 | |
| Selling, General and Administrative Excl. Other | 177 | 163 | 184 | 171 | 157 | 142 | 137 | 139 | 142 | |
| Research and Development | 51 | 46 | 53 | 62 | 60 | 52 | 48 | 47 | 49 | |
| Other Operating Expense | 11 | 8 | 16 | 15 | 17 | 7 | -20 | 11 | 16 | |
| Operating Income | 193 | 209 | 208 | 163 | 113 | 136 | 121 | 158 | 156 | |
| Interest Expense | 38 | 42 | 56 | 53 | 37 | 32 | 38 | 53 | 99 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | -42 | -4 | -5 | -7 | -3 | 4 | 0 | 5 | |
| Net Income Before Taxes | 159 | 125 | 148 | 105 | 69 | 101 | 86 | 105 | 61 | |
| Income Taxes | 17 | 23 | 27 | 16 | 9 | 8 | 9 | 14 | 14 | |
| Consolidated Net Income | 143 | 103 | 120 | 91 | 66 | 97 | 77 | 96 | 168 | |
| Net Income From Continuing Operations | 143 | 103 | 121 | 89 | 60 | 93 | 77 | 91 | 47 | |
| Net Income | 143 | 103 | 120 | 91 | 66 | 97 | 77 | 96 | 168 | |
| EPS (Recurring) | 4.06 | 2.96 | 3.60 | 2.72 | 1.97 | 2.82 | 2.35 | 2.80 | 5.23 | |
| EPS (Basic, Before Extraordinaries) | 4.06 | 2.96 | 3.60 | 2.72 | 1.97 | 2.82 | 2.35 | 2.80 | 5.23 | |
| EPS (Diluted) | 4.01 | 2.89 | 3.40 | 2.69 | 1.96 | 2.80 | 2.33 | 2.77 | 5.15 | |
| EBITDA | 333 | 294 | 333 | 276 | 222 | 225 | 183 | 247 | 253 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 31.03 | 27.14 | 38.98 | 36.83 | 34.93 | 30.57 | 34.85 | 29.04 | 14.81 | |
| Price To Sales Ratio | 2.29 | 1.49 | 2.62 | 2.10 | 1.70 | 2.31 | 2.50 | 2.11 | 2.01 | |
| Gross Margin | 23.28 | 23.08 | 26.85 | 26.48 | 26.07 | 27.60 | 26.65 | 28.22 | 29.88 | |
| Operating Margin | 10.43 | 11.32 | 12.11 | 10.48 | 8.49 | 11.14 | 11.28 | 12.56 | 12.84 | |
| Net Margin | 7.73 | 5.58 | 6.99 | 5.85 | 4.96 | 7.94 | 7.18 | 7.63 | 13.83 | |
| Shares Outstanding | 34 | 35 | 34 | 33 | 33 | 33 | 33 | 33 | 32 | |
| Market Capitalization | 4,231 | 2,745 | 4,506 | 3,270 | 2,259 | 2,824 | 2,679 | 2,654 | 2,440 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Thor Kirk K | Chief Human Resources Officer | Jun 30 '26 | Option Exercise | 0.00 | 6,120 | 0 | 41,102 | Jul 01 |
| Stephens Jim | President, CRM & Neuro | May 15 '26 | Option Exercise | 0.00 | 1,963 | 0 | 6,331 | May 19 |
| Smith Diron | EVP, Chief Financial Officer | May 08 '26 | Option Exercise | 0.00 | 2,063 | 0 | 13,422 | May 12 |
| Harris John A | EVP, Global Ops and Manufactur | Mar 31 '26 | Option Exercise | 0.00 | 3,837 | 0 | 10,499 | Apr 02 |
| Blackwood Lindsay K. | SVP, Gen Counsel & Secretary | Mar 24 '26 | Option Exercise | 0.00 | 3,483 | 0 | 3,483 | Mar 25 |
| Carr Terence | EVP, Qlty & Regulatory Affairs | Mar 24 '26 | Option Exercise | 0.00 | 1,350 | 0 | 1,350 | Mar 25 |
| Thomas Tommy P | VP, Corporate Controller | Mar 13 '26 | Sale | 85.00 | 825 | 70,125 | 4,381 | Mar 17 |
| Khales Payman | President & CEO | Feb 24 '26 | Option Exercise | 0.00 | 43,060 | 0 | 78,799 | Feb 24 |
| Thomas Tommy P | VP, Corporate Controller | Jan 20 '26 | Option Exercise | 0.00 | 337 | 0 | 4,391 | Jan 21 |
| Smith Diron | EVP, Chief Financial Officer | Jan 20 '26 | Option Exercise | 0.00 | 292 | 0 | 11,058 | Jan 21 |
| Thor Kirk K | Chief Human Resources Officer | Jan 20 '26 | Option Exercise | 0.00 | 816 | 0 | 28,750 | Jan 21 |
| Senn Andrew | SVP, Strategy and Business Dev | Jan 20 '26 | Option Exercise | 0.00 | 2,224 | 0 | 12,625 | Jan 21 |
| Khales Payman | President & CEO | Jan 20 '26 | Option Exercise | 0.00 | 1,348 | 0 | 26,434 | Jan 21 |
| Smith Diron | EVP, Chief Financial Officer | Jan 19 '26 | Option Exercise | 0.00 | 1,709 | 0 | 10,766 | Jan 21 |
| Stephens Jim | President, CRM & Neuro | Jan 19 '26 | Option Exercise | 0.00 | 758 | 0 | 2,032 | Jan 21 |